Kluyvera infections in the pediatric population.
In pediatric patients, Kluyvera spp. has emerged as a cause of disease ranging from soft tissue infections to sepsis with multiorgan failure. Successful treatment options include third-generation cephalosporins, tetracycline, aminoglycosides, and fluoroquinolones, but resistance to first- and second-generation cephalosporins persists. Clinicians should be aware of the spectrum of disease and increasing clinical importance associated with this emerging pathogen.
Carter
J Elliot
JE
Department of Pathology, University of South Alabama, Mobile, AL 36617, USA. ecarter@usouthal.edu
Laurini
Javier A
JA
Mizell
Kelly N
KN
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D044086:Kluyvera / Q000302:isolation & purification*; D008297:Male; D009102:Multiple Organ Failure / Q000209:etiology; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents